Pomerantz Law Firm Urges Regeneron Investors to Join Class Action Lawsuit Over Securities Fraud Claims
On January 21, 2025, Pomerantz LLP announced the initiation of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) aimed at protecting shareholders who incurred losses due to alleged securities fraud and related misconduct by the company.
Investors who acquired Regeneron securities during the designated Class Period are encouraged to reach out to Pomerantz LLP to establish eligibility for participating in the lawsuit. Shareholders must act swiftly, as the deadline to petition the court to be appointed as Lead Plaintiff is March 10, 2025. Danielle Peyton, an attorney at Pomerantz, is available to assist potential claimants and recommends including pertinent contact information and details of share purchases.
The class action arises from allegations that Regeneron and specific executives engaged in deceptive practices regarding the distribution and pricing of their products, especially Eylea and Eylea HD. On April 10, 2024, the U.S. Department of Justice revealed a significant inquiry into Regeneron, claiming the company failed to disclose substantial discounts provided to drug distributors, which consequently led to an inflated Average Sales Price (ASP) for these medications. This purported inflation raised Medicare reimbursements unjustly, giving Regeneron a competitive edge over its rivals.
After this was announced, Regeneron's stock experienced a noticeable decline, dropping $31.50 within just two days, settling at $904.70 per share by April 12, 2024. Then, later in the year, on October 31, Regeneron disclosed disappointing third quarter performance numbers that further impacted its market value. Sales for Eylea HD registered only a modest 3% increase year-over-year, significantly falling short of benchmark expectations set by analysts. This disclosure caused the stock to plummet by 9.2%, concluding at $838.20 on the same day.
Founded over eight decades ago, Pomerantz LLP has established a formidable reputation in the realm of class action litigation, particularly in corporate, securities, and antitrust cases. The firm is renowned for its efforts to advocate on behalf of individuals who have suffered due to breaches of fiduciary duties, fraud, and other corporate malpractices. Their track record includes a multitude of multimillion-dollar recoveries, reinforcing their commitment to delivering justice for investors.
Potential claimants are advised to review the complaint and assess their situation as soon as possible, as the implications of not participating in this class action could have lasting repercussions on their financial stake in Regeneron. Interested investors can find more details about the ongoing case and how to join at www.pomerantzlaw.com.
In light of this unfolding situation, investors are advised to remain vigilant regarding Regeneron’s operations and any subsequent announcements from the firm. This class action lawsuit underscores the complexities and risks inherent in pharmaceutical investments, highlighting the necessity for transparency and accountability in corporate governance.
Investors who acquired Regeneron securities during the designated Class Period are encouraged to reach out to Pomerantz LLP to establish eligibility for participating in the lawsuit. Shareholders must act swiftly, as the deadline to petition the court to be appointed as Lead Plaintiff is March 10, 2025. Danielle Peyton, an attorney at Pomerantz, is available to assist potential claimants and recommends including pertinent contact information and details of share purchases.
The class action arises from allegations that Regeneron and specific executives engaged in deceptive practices regarding the distribution and pricing of their products, especially Eylea and Eylea HD. On April 10, 2024, the U.S. Department of Justice revealed a significant inquiry into Regeneron, claiming the company failed to disclose substantial discounts provided to drug distributors, which consequently led to an inflated Average Sales Price (ASP) for these medications. This purported inflation raised Medicare reimbursements unjustly, giving Regeneron a competitive edge over its rivals.
After this was announced, Regeneron's stock experienced a noticeable decline, dropping $31.50 within just two days, settling at $904.70 per share by April 12, 2024. Then, later in the year, on October 31, Regeneron disclosed disappointing third quarter performance numbers that further impacted its market value. Sales for Eylea HD registered only a modest 3% increase year-over-year, significantly falling short of benchmark expectations set by analysts. This disclosure caused the stock to plummet by 9.2%, concluding at $838.20 on the same day.
Founded over eight decades ago, Pomerantz LLP has established a formidable reputation in the realm of class action litigation, particularly in corporate, securities, and antitrust cases. The firm is renowned for its efforts to advocate on behalf of individuals who have suffered due to breaches of fiduciary duties, fraud, and other corporate malpractices. Their track record includes a multitude of multimillion-dollar recoveries, reinforcing their commitment to delivering justice for investors.
Potential claimants are advised to review the complaint and assess their situation as soon as possible, as the implications of not participating in this class action could have lasting repercussions on their financial stake in Regeneron. Interested investors can find more details about the ongoing case and how to join at www.pomerantzlaw.com.
In light of this unfolding situation, investors are advised to remain vigilant regarding Regeneron’s operations and any subsequent announcements from the firm. This class action lawsuit underscores the complexities and risks inherent in pharmaceutical investments, highlighting the necessity for transparency and accountability in corporate governance.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.